Your browser doesn't support javascript.
New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
Williams, Roger; Alessi, Charles; Alexander, Graeme; Allison, Michael; Aspinall, Richard; Batterham, Rachel L; Bhala, Neeraj; Day, Natalie; Dhawan, Anil; Drummond, Colin; Ferguson, James; Foster, Graham; Gilmore, Ian; Goldacre, Raphael; Gordon, Harriet; Henn, Clive; Kelly, Deirdre; MacGilchrist, Alastair; McCorry, Roger; McDougall, Neil; Mirza, Zulfiquar; Moriarty, Kieran; Newsome, Philip; Pinder, Richard; Roberts, Stephen; Rutter, Harry; Ryder, Stephen; Samyn, Marianne; Severi, Katherine; Sheron, Nick; Thorburn, Douglas; Verne, Julia; Williams, John; Yeoman, Andrew.
  • Williams R; Institute of Hepatology, Foundation for Liver Research, London, UK.
  • Alessi C; Public Health England, Leeds, UK.
  • Alexander G; UCL Institute for Liver & Digestive Health, Royal Free Hospital, London, UK.
  • Allison M; Liver Unit, Department of Medicine, Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Aspinall R; Department of Gastroenterology & Hepatology, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
  • Batterham RL; National Institute of Health Research, UCLH Biomedical Research Centre, London, UK.
  • Bhala N; NIHR Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Gastrointestinal and Liver Services, Queen Elizabeth Hospital Birmingham at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Day N; Institute of Hepatology, Foundation for Liver Research, London, UK.
  • Dhawan A; Paediatric Liver, GI and Nutrition Centre, King's College Hospital NHS Foundation Trust, London, UK.
  • Drummond C; Institute of Psychiatry, Psychology & Neuroscience, King's College London and South London and Maudsley NHS Foundation Trust, London, UK.
  • Ferguson J; NIHR Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Foster G; Bart's Liver Centre, Queen Mary University of London, London, UK.
  • Gilmore I; Liverpool Centre for Alcohol Research, University of Liverpool, Liverpool, UK; Alcohol Health Alliance, London, UK. Electronic address: igilmore@liverpool.ac.uk.
  • Goldacre R; Unit of Health Care Epidemiology, Big Data Institute, Nuffield Department of Population Health, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Gordon H; Gastroenterology Department, Hampshire Hospitals Foundation Trust, Winchester, UK.
  • Henn C; Public Health England, Leeds, UK.
  • Kelly D; Liver Unit, Birmingham Women's and Children's Hospital and University of Birmingham, Birmingham, UK.
  • MacGilchrist A; Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • McCorry R; Liver Unit, Royal Victoria Hospital, Belfast, UK.
  • McDougall N; Liver Unit, Royal Victoria Hospital, Belfast, UK.
  • Mirza Z; Emergency Department, West Middlesex University Hospital, London, UK.
  • Moriarty K; British Society of Gastroenterology, London, UK.
  • Newsome P; NIHR Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Pinder R; School of Public Health, Imperial College of Science & Technology, London, UK.
  • Roberts S; Swansea University Medical School, Swansea, UK.
  • Rutter H; Department of Social and Policy Sciences, University of Bath, Bath, UK.
  • Ryder S; NIHR Biomedical Research Centre at Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
  • Samyn M; Paediatric Liver, GI and Nutrition Centre, King's College Hospital NHS Foundation Trust, London, UK.
  • Severi K; Institute of Alcohol Studies, London, UK.
  • Sheron N; Institute of Hepatology, Foundation for Liver Research, London, UK.
  • Thorburn D; UCL Institute for Liver & Digestive Health, Royal Free Hospital, London, UK; Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK.
  • Verne J; Public Health England, Leeds, UK.
  • Williams J; Swansea University Medical School, Swansea, UK.
  • Yeoman A; Aneurin Bevan University Health Board, Newport, UK.
Lancet ; 397(10286): 1770-1780, 2021 05 08.
Article in English | MEDLINE | ID: covidwho-1131898
ABSTRACT
This Review, in addressing the unacceptably high mortality of patients with liver disease admitted to acute hospitals, reinforces the need for integrated clinical services. The masterplan described is based on regional, geographically sited liver centres, each linked to four to six surrounding district general hospitals-a pattern of care similar to that successfully introduced for stroke services. The plan includes the establishment of a lead and deputy lead clinician in each acute hospital, preferably a hepatologist or gastroenterologist with a special interest in liver disease, who will have prime responsibility for organising the care of admitted patients with liver disease on a 24/7 basis. Essential for the plan is greater access to intensive care units and high-dependency units, in line with the reconfiguration of emergency care due to the COVID-19 pandemic. This Review strongly recommends full implementation of alcohol care teams in hospitals and improved working links with acute medical services. We also endorse recommendations from paediatric liver services to improve overall survival figures by diagnosing biliary atresia earlier based on stool colour charts and better caring for patients with impaired cognitive ability and developmental mental health problems. Pilot studies of earlier diagnosis have shown encouraging progress, with 5-6% of previously undiagnosed cases of severe fibrosis or cirrhosis identified through use of a portable FibroScan in primary care. Similar approaches to the detection of early asymptomatic disease are described in accounts from the devolved nations, and the potential of digital technology in improving the value of clinical consultation and screening programmes in primary care is highlighted. The striking contribution of comorbidities, particularly obesity and diabetes (with excess alcohol consumption known to be a major factor in obesity), to mortality in COVID-19 reinforces the need for fiscal and other long delayed regulatory measures to reduce the prevalence of obesity. These measures include the food sugar levy and the introduction of the minimum unit price policy to reduce alcohol consumption. Improving public health, this Review emphasises, will not only mitigate the severity of further waves of COVID-19, but is crucial to reducing the unacceptable burden from liver disease in the UK.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospitalization / Liver Diseases Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Lancet Year: 2021 Document Type: Article Affiliation country: S0140-6736(20)32396-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospitalization / Liver Diseases Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Lancet Year: 2021 Document Type: Article Affiliation country: S0140-6736(20)32396-5